The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects
•2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further 52 individuals became SARS-CoV-2 positive over a 14-day period.•24 subjects found to be SARS-CoV-2 positive at day 14 remained asymptomatic un...
Saved in:
Published in | International journal of infectious diseases Vol. 102; pp. 285 - 288 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Canada
Elsevier Ltd
01.01.2021
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further 52 individuals became SARS-CoV-2 positive over a 14-day period.•24 subjects found to be SARS-CoV-2 positive at day 14 remained asymptomatic until viral clearance.•Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.
The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival.
2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance.
188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2–13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days — less than for those who were asymptomatic on arrival (p < 0.002).
Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir. |
---|---|
AbstractList | •2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further 52 individuals became SARS-CoV-2 positive over a 14-day period.•24 subjects found to be SARS-CoV-2 positive at day 14 remained asymptomatic until viral clearance.•Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.
The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival.
2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance.
188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2–13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days — less than for those who were asymptomatic on arrival (p < 0.002).
Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir. The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival.BACKGROUNDThe frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival.2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance.METHODS2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance.188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2-13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days - less than for those who were asymptomatic on arrival (p < 0.002).RESULTS188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2-13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days - less than for those who were asymptomatic on arrival (p < 0.002).Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.CONCLUSIONAsymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir. Background: The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival. Methods: 2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance. Results: 188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2–13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days — less than for those who were asymptomatic on arrival (p < 0.002). Conclusion: Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir. The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival. 2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance. 188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2-13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days - less than for those who were asymptomatic on arrival (p < 0.002). Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir. |
Author | Atkin, Stephen L. AbdulRahman, AbdulKarim Otoom, Sameer Salman Alsayyad, Adel Al-Qahtani, Manaf AlAli, Salman |
Author_xml | – sequence: 1 givenname: Manaf orcidid: 0000-0002-1523-0429 surname: Al-Qahtani fullname: Al-Qahtani, Manaf email: mqahtani@rcsi-mub.com organization: Bahrain Defense Force Hospital, Bahrain – sequence: 2 givenname: Salman surname: AlAli fullname: AlAli, Salman email: salmanyalali@gmail.com organization: Bahrain Defense Force Hospital, Bahrain – sequence: 3 givenname: AbdulKarim orcidid: 0000-0002-7331-388X surname: AbdulRahman fullname: AbdulRahman, AbdulKarim email: abdulkarim.md@live.com organization: Mohammed bin Khalifa Cardiac Centre, Bahrain – sequence: 4 givenname: Adel surname: Salman Alsayyad fullname: Salman Alsayyad, Adel email: ASayyad@health.gov.bh organization: Ministry of Health, Bahrain – sequence: 5 givenname: Sameer surname: Otoom fullname: Otoom, Sameer email: sotoom@rcsi.com organization: Royal College of Surgeons, Bahrain – sequence: 6 givenname: Stephen L. orcidid: 0000-0002-5887-7257 surname: Atkin fullname: Atkin, Stephen L. email: satkin@rcsi.com organization: Royal College of Surgeons, Bahrain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33157290$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUstu1DAUjVARfcAPsEBZsslgO4kfCCGhgcJIlbopbFhYjn3TccjYUzsZaf4eu1Oqtouy8eP6nHOvfM5pceS8g6J4i9ECI0w_DAs7WLMgiOTCAgn8ojjBnPGqbjE-SmeCcCUYJsfFaYwDQqihlL8qjusat4wIdFL8vlpDuQ2wUyM4DaXvSxX3m-3kN2qyulTOlA_vy8tfq68VFqV1pSq1X_swZdLNrIJyk3WQ8HM3gJ7i6-Jlr8YIb-72s-Ln-ber5Y_q4vL7avnlotJpiKnqe94pIIYwSqEWuOc1apoWsZbptPCeYqMYgOEtbkTdkg61tGs7hBuksRb1WbE66BqvBrkNdqPCXnpl5W3Bh2upQhp-BNk2RlGsGU4NG0yF0koQyqBHPaeNyVqfD1rbuduA0eCmoMZHoo9fnF3La7-TjCJGKEkC7-8Egr-ZIU5yY6OGcVQO_BwlaVrOSM1Fhr572Ou-yT93EoAcADr4GAP09xCMZI6AHGSOgMwRyLUUgUTiT0jaTsk7n-e14_PUTwcqJLd2FoKM2uZYGBuSoek77fP0j0_oerTOajX-gf3_yH8BAKPfRA |
CitedBy_id | crossref_primary_10_1016_j_jobcr_2021_10_001 crossref_primary_10_1016_j_wneu_2021_03_055 crossref_primary_10_1016_j_ijid_2021_02_100 crossref_primary_10_1016_j_tmaid_2021_102127 crossref_primary_10_1038_s41598_023_42754_2 crossref_primary_10_1073_pnas_2109229118 crossref_primary_10_3389_fpubh_2023_1216113 crossref_primary_10_4103_NJM_NJM_113_21 crossref_primary_10_1080_17477778_2023_2189027 crossref_primary_10_1080_23744235_2022_2131899 crossref_primary_10_1016_j_ijbiomac_2021_11_016 crossref_primary_10_1371_journal_pmed_1003987 crossref_primary_10_2139_ssrn_3925475 crossref_primary_10_1016_S2666_5247_22_00259_2 crossref_primary_10_3390_ijerph20054651 crossref_primary_10_1098_rsif_2022_0498 crossref_primary_10_3389_fmed_2023_1132476 crossref_primary_10_1371_journal_pone_0271259 crossref_primary_10_1007_s12070_022_03112_2 crossref_primary_10_1007_s40314_021_01592_6 crossref_primary_10_1093_jtm_taab037 crossref_primary_10_1001_jamanetworkopen_2021_37257 crossref_primary_10_1016_j_ijregi_2022_02_007 crossref_primary_10_2147_IJGM_S374090 crossref_primary_10_1016_j_psychres_2023_115631 crossref_primary_10_1016_j_jinf_2024_106238 crossref_primary_10_1016_j_chaos_2024_114695 crossref_primary_10_2147_IJGM_S396357 crossref_primary_10_2196_27254 crossref_primary_10_24018_ejmed_2022_4_1_1213 crossref_primary_10_3389_fpubh_2021_644199 crossref_primary_10_34172_ehsj_2023_05 crossref_primary_10_1016_j_curtheres_2024_100733 crossref_primary_10_4178_epih_e2022085 crossref_primary_10_1038_s41598_022_06159_x crossref_primary_10_1016_j_puhip_2021_100145 crossref_primary_10_7759_cureus_24194 |
Cites_doi | 10.2807/1560-7917.ES.2020.25.10.2000180 10.7326/M20-3012 10.2807/1560-7917.ES.2020.25.5.2000062 10.1111/anae.15072 10.7326/M20-0504 10.1016/S2214-109X(20)30074-7 10.1056/NEJMc2001737 10.2807/1560-7917.ES.2020.25.3.2000045 10.1056/NEJMoa2008457 10.1016/j.jaut.2020.102433 10.1016/j.ijid.2020.03.020 |
ContentType | Journal Article |
Copyright | 2020 The Author(s) Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. 2020 The Author(s) 2020 |
Copyright_xml | – notice: 2020 The Author(s) – notice: Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. – notice: 2020 The Author(s) 2020 |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1016/j.ijid.2020.10.091 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1878-3511 |
EndPage | 288 |
ExternalDocumentID | oai_doaj_org_article_54da61c71ae24169aca9267ef0f864d9 PMC7607262 33157290 10_1016_j_ijid_2020_10_091 S1201971220322943 |
Genre | Journal Article |
GeographicLocations | Bahrain |
GeographicLocations_xml | – name: Bahrain |
GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW NCXOZ RIG AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c572t-ff8bae2d2766e391f8304450757c0758f61da7eed85149352b056b5b0140c1c93 |
IEDL.DBID | IXB |
ISSN | 1201-9712 1878-3511 |
IngestDate | Wed Aug 27 01:31:34 EDT 2025 Thu Aug 21 18:07:11 EDT 2025 Sun Aug 24 03:47:45 EDT 2025 Thu Apr 03 07:05:17 EDT 2025 Tue Jul 01 04:29:56 EDT 2025 Thu Apr 24 22:52:18 EDT 2025 Fri Feb 23 02:44:41 EST 2024 Tue Aug 26 16:33:02 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 Screening SARS-CoV-2 Symptoms |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c572t-ff8bae2d2766e391f8304450757c0758f61da7eed85149352b056b5b0140c1c93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Joint senior authors. |
ORCID | 0000-0002-7331-388X 0000-0002-5887-7257 0000-0002-1523-0429 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1201971220322943 |
PMID | 33157290 |
PQID | 2458723892 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_54da61c71ae24169aca9267ef0f864d9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7607262 proquest_miscellaneous_2458723892 pubmed_primary_33157290 crossref_primary_10_1016_j_ijid_2020_10_091 crossref_citationtrail_10_1016_j_ijid_2020_10_091 elsevier_sciencedirect_doi_10_1016_j_ijid_2020_10_091 elsevier_clinicalkey_doi_10_1016_j_ijid_2020_10_091 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-01-01 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Canada |
PublicationPlace_xml | – name: Canada |
PublicationTitle | International journal of infectious diseases |
PublicationTitleAlternate | Int J Infect Dis |
PublicationYear | 2021 |
Publisher | Elsevier Ltd The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases – name: Elsevier |
References | Corman, Landt, Kaiser, Molenkamp, Meijer, Chu (bib0025) 2020; 25 Fogarty, Townsend, Ni Cheallaigh, Bergin, Martin-Loeches, Browne (bib0030) 2020 Zou, Ruan, Huang, Liang, Huang, Hong (bib0065) 2020; 382 Mizumoto, Kagaya, Zarebski, Chowell (bib0045) 2020; 25 Nishiura, Kobayashi, Miyama, Suzuki, Jung, Hayashi (bib0050) 2020; 94 Carenzo, Costantini, Greco, Barra, Rendiniello, Mainetti (bib0015) 2020 CDC (bib0020) 2020 Rothan, Byrareddy (bib0060) 2020; 109 Oran, Topol (bib0055) 2020 Backer, Klinkenberg, Wallinga (bib0010) 2020; 25 Arons, Hatfield, Reddy, Kimball, James, Jacobs (bib0005) 2020; 382 Lauer, Grantz, Bi, Jones, Zheng, Meredith (bib0040) 2020; 172 Hellewell, Abbott, Gimma, Bosse, Jarvis, Russell (bib0035) 2020; 8 Rothan (10.1016/j.ijid.2020.10.091_bib0060) 2020; 109 Arons (10.1016/j.ijid.2020.10.091_bib0005) 2020; 382 CDC (10.1016/j.ijid.2020.10.091_bib0020) 2020 Mizumoto (10.1016/j.ijid.2020.10.091_bib0045) 2020; 25 Oran (10.1016/j.ijid.2020.10.091_bib0055) 2020 Backer (10.1016/j.ijid.2020.10.091_bib0010) 2020; 25 Fogarty (10.1016/j.ijid.2020.10.091_bib0030) 2020 Carenzo (10.1016/j.ijid.2020.10.091_bib0015) 2020 Lauer (10.1016/j.ijid.2020.10.091_bib0040) 2020; 172 Zou (10.1016/j.ijid.2020.10.091_bib0065) 2020; 382 Hellewell (10.1016/j.ijid.2020.10.091_bib0035) 2020; 8 Corman (10.1016/j.ijid.2020.10.091_bib0025) 2020; 25 Nishiura (10.1016/j.ijid.2020.10.091_bib0050) 2020; 94 |
References_xml | – year: 2020 ident: bib0055 article-title: Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review publication-title: Ann Intern Med – volume: 94 start-page: 154 year: 2020 end-page: 155 ident: bib0050 article-title: Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) publication-title: Int J Infect Dis – year: 2020 ident: bib0020 article-title: Pandemic Planning Scenarios – year: 2020 ident: bib0030 article-title: COVID-19 coagulopathy in caucasian patients publication-title: Br Haematol – year: 2020 ident: bib0015 article-title: Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy publication-title: Anaesthesia – volume: 25 year: 2020 ident: bib0025 article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR publication-title: Euro Surveill – volume: 25 year: 2020 ident: bib0010 article-title: Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020 publication-title: Euro Surveill – volume: 25 year: 2020 ident: bib0045 article-title: Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 publication-title: Euro Surveill – volume: 382 start-page: 2081 year: 2020 end-page: 2090 ident: bib0005 article-title: Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility publication-title: N Engl J Med – volume: 109 year: 2020 ident: bib0060 article-title: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak publication-title: J Autoimmunity – volume: 172 start-page: 577 year: 2020 end-page: 582 ident: bib0040 article-title: The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application publication-title: Ann Intern Med – volume: 382 start-page: 1177 year: 2020 end-page: 1179 ident: bib0065 article-title: SARS-CoV-2 viral load in upper respiratory specimens of infected patients publication-title: N Engl J Med – volume: 8 start-page: e488 year: 2020 end-page: 96 ident: bib0035 article-title: Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts publication-title: Lancet Global Health – volume: 25 issue: 10 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0045 article-title: Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.10.2000180 – year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0055 article-title: Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review publication-title: Ann Intern Med doi: 10.7326/M20-3012 – volume: 25 issue: 5 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0010 article-title: Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.5.2000062 – year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0015 article-title: Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy publication-title: Anaesthesia doi: 10.1111/anae.15072 – volume: 172 start-page: 577 issue: 9 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0040 article-title: The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application publication-title: Ann Intern Med doi: 10.7326/M20-0504 – volume: 8 start-page: e488 issue: 4 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0035 article-title: Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts publication-title: Lancet Global Health doi: 10.1016/S2214-109X(20)30074-7 – year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0030 article-title: COVID-19 coagulopathy in caucasian patients publication-title: Br Haematol – volume: 382 start-page: 1177 issue: 12 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0065 article-title: SARS-CoV-2 viral load in upper respiratory specimens of infected patients publication-title: N Engl J Med doi: 10.1056/NEJMc2001737 – year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0020 – volume: 25 issue: 3 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0025 article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.3.2000045 – volume: 382 start-page: 2081 issue: 22 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0005 article-title: Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility publication-title: N Engl J Med doi: 10.1056/NEJMoa2008457 – volume: 109 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0060 article-title: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak publication-title: J Autoimmunity doi: 10.1016/j.jaut.2020.102433 – volume: 94 start-page: 154 year: 2020 ident: 10.1016/j.ijid.2020.10.091_bib0050 article-title: Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2020.03.020 |
SSID | ssj0004668 |
Score | 2.462312 |
Snippet | •2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further... The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated... Background: The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was... |
SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 285 |
SubjectTerms | Adult Aged Aged, 80 and over Asymptomatic Infections - epidemiology Bahrain - epidemiology Cohort Studies COVID-19 COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Testing Female Humans Male Middle Aged Prevalence Quarantine SARS-CoV-2 Screening Symptoms |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yBxFEdP2qX0TwJtXmuznq6rIKqxdXFjyUtEmwi3bGmc7B_973mrZMFXYvXgaaSWZI3i99v6bv_R4hL3xUSujAc8Ebn0sRWG4jl7kEbgoY0ppLzB0-_aRPzuTHc3W-V-oLY8KSPHBauNdKeqdZY5gL4Gy0dY2zXJsQi1hq6YfUPfB508PUnBGZkuDAveXWMD6my6TIrvaiRY1Qjg2vCssWLmlQ7l94pn-Z598BlHse6fg2uTVSSfomTeEOuRa6Q3L9dHxZfkhupiM5mjKN7pJvAAm63qC-N25nuorUbX__XPerQbaVus7T_eujz18_vMuZpW1HHcVKupseB_0CVDksMBGg_67Gg5ztPXJ2_P7L0Uk-1lbIG2V4n8dY1rCinhutg7AslqKQEsihMg18lFEz7ww4UGBk0gJLq4Ep1arGB7KGNVbcJwfdqgsPCQ1ReXD0hXFOyqCKWnhWayec81oBYckIm5a3akbhcax_8aOaIswuKjRJhSbBNjBJRl7OY9ZJduPS3m_RanNPlMweGgBI1Qik6iogZURMNq-mrFS4j8IPtZf-tZpHjZwlcZErxz2fYFXBhsa3NK4Lq9224lKVWAnO8ow8SDCbJyYEA-vZIiNmAcDFzJffdO33QTTc6MJwzR_9j6V6TG5wDO0ZTqKekIN-swtPgZv19bNhG_4BKoEziQ priority: 102 providerName: Directory of Open Access Journals |
Title | The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971220322943 https://dx.doi.org/10.1016/j.ijid.2020.10.091 https://www.ncbi.nlm.nih.gov/pubmed/33157290 https://www.proquest.com/docview/2458723892 https://pubmed.ncbi.nlm.nih.gov/PMC7607262 https://doaj.org/article/54da61c71ae24169aca9267ef0f864d9 |
Volume | 102 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9RAEG7WPYggi66v-Bha8CbZSb_TR3d0WZVVRFcGPIROuqNZ3Mw4kzl48bdblccwUVjBSyCd6iSdqnR96VR9RcgzXyoldOCx4IWPpQgstiWXsQRsCjakNZeYO3z2Tp-eyzdzNd8jsyEXBsMq-7m_m9Pb2bpvmfZPc7qsqulHBr7LGsaxBji3Ehk_hUzbJL758U5uZJcOB8IxSveJM12MV3VRIVsox4ajxLKRc2o5_Ec-6m8M-mco5Y5vOrlFDnpQSV90932b7IX6kFw_63-bH5Kb3eIc7XKO7pAvYBx0uUKmbxwwXZTUrX9eLptFS-BKXe3p7v7s_efXL2NmaVVTR7Gm7qrBTj_AvhyWmgggv8lxSWd9l5yfvPo0O437KgtxoQxv4rJMcxe450brICwrU5FICTBRmQI2aamZdwZcKWAzaQGv5YCZcpXjp1nBCivukf16UYcHhIZSeXD5iXFOyqCSXHiWayec81oBdIkIGx5vVvQU5FgJ43s2xJpdZKiSDFWCbaCSiDzf9ll2BBxXSh-j1raSSJ7dNixWX7PeejIlvdOsMAyGDXjUusJZrk0okzLV0tuIiEHn2ZCfCjMqnKi68tJq22tkwf_s93Qwqwxebfxf4-qw2KwzLlWKNeEsj8j9zsy2AxOCgfZsEhEzMsDRyMdH6upbSx9udGK45g__834fkRsc43raZajHZL9ZbcITAGZNPiHXjn6xSbusMWnfQti-_ZD-BsZlNpg |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWRYKVEILlFZ5G4oZC43d9ZAurFrbLgV1UiUPkJA5ktSSlTQ_8e2byqBqQFolLpDjjxPaMPV_seRDyKsuVEtrzUPA0C6XwLLQ5l6EEbAoypDWX6Ds8P9XTc_lhoRZ7ZNL7wqBZZbf2t2t6s1p3JaNuNEfLohh9ZqC7rGEcc4BzK8U1ch3QgMH8DbPF0Y5zZOsPB9QhkneeM62RV3FRYLhQjgVvIssG2qkJ4j9QUn-D0D9tKXeU0_EdcrtDlfRt2_C7ZM-Xh-TGvDs3PyS32t052jod3SNfQTrocoWhvrHHtMqpW__6sayrJoIrdWVGd-8nn77M3oXM0qKkjmJS3VWNlX6CgDnMNeGBfpPgns76Pjk_fn82mYZdmoUwVYbXYZ6PE-d5xo3WXliWj0UkJeBEZVK4jHPNMmdAlwI4kxYAWwKgKVEJ_pulLLXiAdkvq9I_ItTnKgOdHxnnpPQqSkTGEu2Ec5lWgF0CwvrhjdMuBjmmwriMe2OzixhZEiNLsAxYEpDX2zrLNgLHldRHyLUtJUbPbgqq1be4E59YycxplhoG3QZAal3qLNfG51E-1jKzARE9z-PeQRWWVHhRceWn1bbWQIT_We9lL1YxzG08sHGlrzbrmEs1xqRwlgfkYStm244JwYB7NgqIGQjgoOfDJ2XxvYkfbnRkuOaP_7O9L8jN6dn8JD6ZnX58Qg44Gvk0e1JPyX692vhngNLq5HkzC38DeBo2zw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prevalence+of+asymptomatic+and+symptomatic+COVID-19+in+a+cohort+of+quarantined+subjects&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Al-Qahtani%2C+Manaf&rft.au=AlAli%2C+Salman&rft.au=AbdulRahman%2C+AbdulKarim&rft.au=Salman+Alsayyad%2C+Adel&rft.date=2021-01-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.eissn=1878-3511&rft.volume=102&rft.spage=285&rft.epage=288&rft_id=info:doi/10.1016%2Fj.ijid.2020.10.091&rft.externalDocID=S1201971220322943 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |